EvolveImmune Targets Lymphoma With Novel T-Cell Engagers Harnessing CD2

 
• By Ayisha Sharma

Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing T cell exhaustion, with a first-in-human trial planned for 2024.  

Emerging Company Profile: EvolveImmune Therapeutics
The EVOLVE Platform Is Designed To Address T-Cell Exhaustion • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs